Treatment results and status of the patients according to their eligibility criteria in hierarchical order
| . | (1) Resistant to protocol Ia . | (2) t(9,22) . | (3) Infants t(4;11) or CD10− . | (4) PPR-only . | Total . | % . |
|---|---|---|---|---|---|---|
| Total | 42 | 26 | 11 | 119 | 198 | |
| Deaths in protocol Ia | 0 | 0 | 1 | 2 | 3 | 1.5 |
| Resistant | 113-150 | 0 | 0 | 0 | 11 | 5.6 |
| CR | 313-151 | 26 | 10 | 117 | 184 | 92.9 |
| Relapses | 16 | 11 | 3 | 25 | 553-152 | 27.8 |
| Marrow | 13 | 9 | 3 | 21 | 46 | |
| Marrow + CNS | 0 | 1 | 0 | 0 | 1 | |
| Marrow + Testis | 2 | 1 | 0 | 1 | 4 | |
| CNS | 1 | 0 | 0 | 3 | 4 | |
| Deaths in CCR | 3 | 1 | 1 | 5 | 103-153 | 5.0 |
| CCR | 12 | 14 | 6 | 87 | 119 | 60.1 |
| 4-year EFS | 25.6 (7.1) | 46.0 (11.6) | 54.6 (15.0) | 70.1 (4.7) | 56.5 (3.9) | |
| 4-year survival | 36.0 (8.1) | 50.7 (13.3) | 54.6 (15.0) | 75.9 (4.3) | 62.8 (3.9) | |
| 4-year EFS (censoring BMT first CR) | 21.1 (7.7) | 47.6 (12.9) | 58.4 (16.3) | 70.2 (5.1) | 57.2 (4.2) |
| . | (1) Resistant to protocol Ia . | (2) t(9,22) . | (3) Infants t(4;11) or CD10− . | (4) PPR-only . | Total . | % . |
|---|---|---|---|---|---|---|
| Total | 42 | 26 | 11 | 119 | 198 | |
| Deaths in protocol Ia | 0 | 0 | 1 | 2 | 3 | 1.5 |
| Resistant | 113-150 | 0 | 0 | 0 | 11 | 5.6 |
| CR | 313-151 | 26 | 10 | 117 | 184 | 92.9 |
| Relapses | 16 | 11 | 3 | 25 | 553-152 | 27.8 |
| Marrow | 13 | 9 | 3 | 21 | 46 | |
| Marrow + CNS | 0 | 1 | 0 | 0 | 1 | |
| Marrow + Testis | 2 | 1 | 0 | 1 | 4 | |
| CNS | 1 | 0 | 0 | 3 | 4 | |
| Deaths in CCR | 3 | 1 | 1 | 5 | 103-153 | 5.0 |
| CCR | 12 | 14 | 6 | 87 | 119 | 60.1 |
| 4-year EFS | 25.6 (7.1) | 46.0 (11.6) | 54.6 (15.0) | 70.1 (4.7) | 56.5 (3.9) | |
| 4-year survival | 36.0 (8.1) | 50.7 (13.3) | 54.6 (15.0) | 75.9 (4.3) | 62.8 (3.9) | |
| 4-year EFS (censoring BMT first CR) | 21.1 (7.7) | 47.6 (12.9) | 58.4 (16.3) | 70.2 (5.1) | 57.2 (4.2) |
Eligibility criteria are in hierarchical order. Thus, column (1) counts all patients who were resistant to induction (protocol Ia), regardless of the remaining features and so on for the subsequent columns. Consequently, column (4) identifies the patients who were defined as HR only because of their poor response to prednisone (they achieved CR and were negative for t(9;22) or t(4;11) translocation, PPR-only).
These 11 patients did not achieve remission by the end of consolidation therapy.
These 31 patients, who were not in CR after protocol Ia, achieved remission by the end of consolidation (block) therapy.
Two of these relapses occurred after BMT in first CR.
Six of these deaths were attributed to transplantation-related events.